Azathioprine myelosuppression in multiple sclerosis: Characterizing thiopurine methyltransferase polymorphisms

Multiple Sclerosis

Volumn 12, Issue 1, 2006, Pages 108-111

  Frohman, Elliot M ^a   Havrdova, E ^c   Levinson, B ^b   Slanar, O ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Azathioprine; Methytransferase; Polymorphism; Thiopurine

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CYANOCOBALAMIN; DEXAMETHASONE; THIOPURINE METHYLTRANSFERASE;

ADULT; ARTICLE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CASE REPORT; DIZZINESS; DNA POLYMORPHISM; DRUG WITHDRAWAL; DYSPNEA; ENZYME DEFICIENCY; FATIGUE; FEMALE; HEADACHE; HEMATOLOGIC DISEASE; HEMATOMA; HOMOZYGOSITY; HUMAN; MULTIPLE SCLEROSIS; PANCYTOPENIA; PARESTHESIA; RETREATMENT; VERTIGO;

ADOLESCENT; AZATHIOPRINE; FEMALE; HOMOZYGOTE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLTRANSFERASES; MIDDLE AGED; MULTIPLE SCLEROSIS; PANCYTOPENIA; POLYMORPHISM, GENETIC; VARIATION (GENETICS);

EID: 31644433606     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135248506ms1249cr     Document Type: Article

References (18)

1. Goodin D, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD et al. Disease modifying therapies in multiple sclerosis. Neurology 2002; 58: 169-78.
2. Juel VC, Massey JM. Autoimmune myasthenia gravis: recommendations for treatment and immunologic modulation. Curr Treat Options Neurol 2005; 7: 3-14.
3. Grogan PM, Katz JS. Inflammatory myopathies. Curr Treat Options Neurol 2004; 6: 155-61.
4. Katz JS, Saperstein DS. Chronic inflammatory demyelinating polyneuropathy. Curr Treat Options Neurol 2003; 5: 357-64.
5. Tidd DM, Paterson ARP. A biochemical mechanism for the delayed cytotoxic reactions of 6-mercaptopurine. Cancer Res 1974; 34: 738-46.
6. Maraithias VM, Sawicki MJ, Bolton PH. 6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation. Nucleic Acids Res 1999; 27: 2860-66.
7. Weinshilboum RM, Sladek S. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Human Genet 1980; 32: 651-62.
8. Lewis RW, Olivier G. In vitro oxidation of 6-MP and its metallocomplexes by xanthine oxidase. Res Commun Chem Pathol Pharmacol 1977; 18: 377-80.
9. Schultz E, von Ahsen M, Oellerich M. Genotyping of eight thiopurine methyltransferase mutations: threecolor multiplexing, two-color/shared anchor, and fluorescence-quenching hybridization probe assays based on thermodynamic nearest-neighbor probe design. Clin Chem 2000; 46: 1728-37.
10. Indjova D, Atanasova S, Shipkiva M, Armstrong VW, Oellerich M, Svinarov D. Phenotypic and genotypic analysis of thiopurine s-methyltransferase polymorphism in the Bulgarian population. Ther Drug Monit 2003; 25: 631-36.
11. Lennard L, Van Loon JA, Weinshilboum. RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-54.
12. Clunie GPR, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology 2004; 43: 13-18.
13. Evans WE. Pharmacogenetics of thiopurine s-methyltransferase and thiopurine therapy. Ther Drug Monit 2004; 26: 186-91.
14. Coulthard SA, Rabello C, Robson J. A comparison of molecular and enzyme-based assays for the detection of thiopurine methyltransferase mutations. Br J Haematol 2000; 110: 599-604.
15. Veenstra DL, Higashi MK, Phillips KA. [electronic resource] Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000; 2: E29.
16. Oh KT, Anis AH, Bae SC. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology 2004; 43: 156-63.
17. Tavadia SM, Tdlarski PR, Reis MD, Mittmann N, Pinkerton PH, Shear N et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42: 628-32.
18. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost effectiveness of screening for thiopurine s-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29: 2507-12.